Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (261-270 of 635) with videos related to

Pageof 64
Sort By:
American Heart Journal|May 16, 2016
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trialJeffrey S Berger, Brian G Katona, W Schuyler Jones, et al.
The New England Journal of Medicine|June 28, 2002
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunctionRonnier J Aviles, Arman T Askari, Bertil Lindahl, et al.
Diabetologia|August 27, 2021
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA<sub>1c</sub>, disease duration and treatment intensity: results from the CANVAS ProgramTamara K Young, Jing-Wei Li, Amy Kang, et al.
The American Journal of Medicine|December 6, 2003
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromesJohn H Alexander, Robert A Harrington, Manju Bhapkar, et al.
International Journal of Cardiology|December 5, 2013
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
Circulation. Genomic and Precision Medicine|April 11, 2023
Accelerated Epigenetic Aging Is Associated With Multiple Cardiometabolic, Hematologic, and Renal Abnormalities: A Project Baseline Health SubstudyBest Uchehara, Lydia Coulter Kwee, Jessica Regan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 14, 2025
SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome TrialsMegumi Oshima, Luke Buizen, Niels Jongs, et al.
Journal of the American Heart Association|January 19, 2024
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE TrialAbhinav Sharma, Amir Razaghizad, Abdulaziz Joury, et al.
American Heart Journal|June 20, 2017
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Circulation. Cardiovascular Interventions|January 1, 2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary InterventionNeal N Sawlani, Robert A Harrington, Gregg W Stone, et al.
Pageof 64

Showing results (261-270 of 635) with videos related to

Sort By:
Pageof 64
American Heart Journal|May 16, 2016
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trialJeffrey S Berger, Brian G Katona, W Schuyler Jones, et al.
The New England Journal of Medicine|June 28, 2002
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunctionRonnier J Aviles, Arman T Askari, Bertil Lindahl, et al.
Diabetologia|August 27, 2021
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA<sub>1c</sub>, disease duration and treatment intensity: results from the CANVAS ProgramTamara K Young, Jing-Wei Li, Amy Kang, et al.
The American Journal of Medicine|December 6, 2003
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromesJohn H Alexander, Robert A Harrington, Manju Bhapkar, et al.
International Journal of Cardiology|December 5, 2013
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
Circulation. Genomic and Precision Medicine|April 11, 2023
Accelerated Epigenetic Aging Is Associated With Multiple Cardiometabolic, Hematologic, and Renal Abnormalities: A Project Baseline Health SubstudyBest Uchehara, Lydia Coulter Kwee, Jessica Regan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 14, 2025
SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome TrialsMegumi Oshima, Luke Buizen, Niels Jongs, et al.
Journal of the American Heart Association|January 19, 2024
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE TrialAbhinav Sharma, Amir Razaghizad, Abdulaziz Joury, et al.
American Heart Journal|June 20, 2017
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Circulation. Cardiovascular Interventions|January 1, 2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary InterventionNeal N Sawlani, Robert A Harrington, Gregg W Stone, et al.
Pageof 64